Nothing Special   »   [go: up one dir, main page]

CN114432276A - 一种细菌响应性微针贴片及其制备方法和应用 - Google Patents

一种细菌响应性微针贴片及其制备方法和应用 Download PDF

Info

Publication number
CN114432276A
CN114432276A CN202210098241.9A CN202210098241A CN114432276A CN 114432276 A CN114432276 A CN 114432276A CN 202210098241 A CN202210098241 A CN 202210098241A CN 114432276 A CN114432276 A CN 114432276A
Authority
CN
China
Prior art keywords
microneedle
responsive
microneedle patch
cypate
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210098241.9A
Other languages
English (en)
Other versions
CN114432276B (zh
Inventor
王建浩
雷晓玲
周心霈
李孟金
邱琳
周舒文
崔朋飞
王程
高子涵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changzhou University
Original Assignee
Changzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changzhou University filed Critical Changzhou University
Priority to CN202210098241.9A priority Critical patent/CN114432276B/zh
Publication of CN114432276A publication Critical patent/CN114432276A/zh
Application granted granted Critical
Publication of CN114432276B publication Critical patent/CN114432276B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0053Methods for producing microneedles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

本发明属于生物医药领域,具体涉及一种细菌响应性微针贴片及其制备方法和应用,微针贴片由微针贴片、细菌响应性载药纳米颗粒、聚合物基质组成。明胶纳米粒子自组装并通过脱水缩合反应与抗菌肽耦合,形成细菌响应性载药纳米颗粒AMP‑Cypate@GNP,并与微针贴片进一步整合制成细菌响应性微针贴片。将其应用到感染部位时,微针会穿透胞外聚合物并物理破坏细菌生物膜的结构,在聚合物微针快速溶解后,明胶纳米粒暴露于由常驻微生物产生的明胶酶而解离,从而导致接枝的抗菌肽触发释放到细菌生物膜基质中。与传统的AMP‑Cypate局部使用相比,具有新型酶感应基质的智能贴片为慢性伤口感染提供了一种有效的潜在治疗方法。

Description

一种细菌响应性微针贴片及其制备方法和应用
技术领域
本发明属于生物医药领域,具体涉及一种细菌响应性微针贴片及其制备方法和应用。
背景技术
慢性伤口,如糖尿病足、压疮、肿瘤伤口和手术部位感染不愈合,严重危及人们的身心健康,并造成巨大的医疗负担。创伤发生后,机体会产生一系列的生理事件来修复损伤,包括止血、炎症、增殖和重塑,细菌感染后会干扰这四个伤口愈合级联的正常协调过程,且细菌诱导的严重伤口感染往往伴随着生物膜的存在。细菌生物膜已被确定为慢性伤口的主要原因。生物膜是附着在受伤组织表面的细菌集合,它很难被机体的免疫机制清除,且对抗生素治疗不敏感。
在“后抗生素时代”的阴影下,虽然许多抗菌策略对浮游细菌有效,但大多数抗菌药物不能处理生物膜。载有抗菌药物的微针贴片(MN)可以实现抗菌治疗和组织再生,被公认为对抗皮肤慢性伤口的最有效方法之一。具有适当长度的MN可以穿透表皮在皮肤中形成通道,同时避免与毛细血管和神经接触,具有微创和无痛的递送策略,可到达皮肤下形成的生物膜。研究人员开发了多种MN,这些MN由抗菌材料组成,例如壳聚糖、抗菌银纳米颗粒、抗菌肽(AMP)、和生物活性提取物等。例如,已开发出含有抗菌剂氯霉素的MN,并用于处理细菌生物膜。MN可以穿透生物膜并促进氯霉素响应细菌群落的释放,从而显着降低药物的脱靶毒性。因此,装有活性再生剂和抗菌药物的MN有望对抗感染引起的慢性伤口。
发明内容
本发明的目的是提供一种能有效抗菌且促进伤口愈合的细菌响应性微针贴片及其制备方法和应用,将功能性纳米材料与MN结合开发一种由物理惰性聚合物PVP K-30和重组III型胶原蛋白制成的可降解微针贴片,可将抗菌药物递送至感染慢性伤口的病灶部位。本发明制备的微针贴片具有较好的促伤口愈合效果,在抑菌、细菌感染伤口的光热治疗方面均有广泛的应用前景。
为了实现上述目的,本发明采用如下技术方案:
本发明提供的细菌响应性微针贴片由微针贴片、细菌响应性载药纳米颗粒AMP-Cypate@GNP和聚合物基质组成;
聚合物基质由生物相容性良好的物理惰性聚合物PVP K-30和重组人III型胶原蛋白(Col III)组成,其制备方法为:将PVP溶于超纯水中(1g PVP加1mL超纯水),加入Col III0.20g混合,配置成混合溶液,4℃保存备用。
细菌响应性载药纳米颗粒AMP-Cypate@GNP是由明胶纳米颗粒(GNP)自组装并通过脱水缩合反应与抗菌肽(AMP-Cypate)耦合形成。明胶纳米颗粒表面含有氨基,抗菌肽序列N端有羧基,通过氨基与羧基脱水缩合反应偶联制得细菌响应性载药纳米颗粒AMP-Cypate@GNP,具体步骤如下:
首先,使用MBHA树脂5倍当量的氨基酸,加入HBTU和HOBt并在DMF中激活偶联,每次持续45分钟。
其次,使用哌啶/DMF(20%,v/v)脱去氨基酸上的Fmoc保护基团,每次持续30分钟。重复上述步骤直至序列合成,再使用TFA/TIS/DCM(1:5:94)将序列N端的Fmoc基团切割掉,N端暴露的氨基与5倍过量的游离Cypate在DIPEA存在的情况下偶联12小时,形成序列AMP-Cypate。通过TFA、EDT、去离子水和TIS(94:2.5:2.5:1,v/v/v/v)的裂解混合物将肽链AMP-Cypate从树脂上切割下来,并通过高效液相进行制备纯化。AMP-Cypate的分子量通过LC-MS确认:m/z计算为[M+2H]2+1076.9,实测值1076.3。
最后,将5mL GNP(4mg/mL)、2mg EDC和2mg NHS在pH≈7下连续搅拌30分钟,以激活明胶纳米颗粒的羧基。将AMP-Cypate滴加到GNP溶液中。将pH值调至7后,将混合物超声处理30分钟。最后,将溶液离心除去未反应的AMP-Cypate,用PBS洗涤3次,冻干得到AMP-Cypate@GNP。
本发明还提供了上述微针贴片的制备方法,具体为:
(1)将约0.2mL浓度为10μg/mL载药纳米颗粒(AMP-Cypate@GNP)的乙醇悬浮液浇注到装载有微针贴片的模具上,将覆盖的模具以2000g离心并在空气流下干燥,该过程重复三遍;
(2)将约1mL聚合物基质溶液浇注到微针模具上,将模具以2200g离心15分钟;在37℃的烘箱中干燥48小时后,小心地剥离微针贴片,将所得微针贴片储存在密封的孔板中以供进一步研究。
本发明细菌响应性微针贴片由载药纳米颗粒和聚合物基质组成。明胶分子可以自组装并通过脱水缩合反应与抗菌肽耦合,形成AMP-Cypate@GNP,并与微针贴剂进一步整合。当应用到感染部位时,微针就会穿透EPS并物理破坏细菌生物膜的结构。在聚合物微针快速溶解后,GNP暴露于由常驻微生物产生的明胶酶而解离,从而导致接枝的AMP-Cypate触发释放到细菌生物膜基质中。与传统的AMP-Cypate局部使用相比,具有新型酶感应基质的智能贴片为慢性伤口感染提供了一种有效的潜在治疗方法。
相比现有技术,本发明具有如下有益效果:
(1)本发明包含的细菌响应性载药纳米颗粒AMP-Cypate@GNP是通过Fmoc固相合成法制备抗菌肽,并将荧光染料Cypate复合偶联在抗菌肽上。抗菌肽AMP-Cypate合成后,再采用去溶剂法合成GNP,并通过脱水缩合将明胶纳米粒与Cypate偶联的肽链结合。载药纳米粒中引入荧光染料Cypate进行光热(PTT)抗菌,与抗菌肽(AMP)产生协同抗菌作用。
(2)本发明微针贴片制备简单,成本低廉,为大规模制备奠定了基础。
(3)微针材料包含抗菌颗粒和胶原蛋白,可以穿透细菌生物膜,而负载的抗菌颗粒仅响应细菌群落的活性而释放,非常适用于治疗伤口和其他容易感染的部位。
附图说明:
图1为载药纳米颗粒AMP-Cypate@GNP的透射电子显微镜(TEM)照片;
图2为微针贴片的数码照片;
图3为微针贴片的扫描电子显微镜(SEM)图片;
图4为罗丹明B(Rho)标记的微针贴片装载FITC标记的GNP的荧光倒置显微镜图像。(明胶纳米粒沉积在微针针尖,显示绿色,微针基质显示红色);
图5为载药纳米颗粒AMP-Cypate@GNP在有或没有激光照射的情况下的杀菌活性测定;
图6为近红外激光照射前后与AMP-Cypate@GNP孵育的金黄色葡萄球菌的活/死染色测定;
图7为载药纳米粒的生物相容性测定结果;
图8为微针穿刺大鼠足部皮肤的数码图片;
图9为微针贴片在体内治疗大鼠足部葡萄球菌感染伤口20天内的伤口愈合照片及感染伤口区域愈合面积的量化图。伤口愈合率的值(原始伤口的百分比)代表来自三个独立实验的平均值;
图10为细菌响应性微针贴片应用在金黄色葡萄球菌感染的糖尿病大鼠足部伤口的示意图。
具体实施方式
以下结合实施例对本发明进行详细阐述,但这些实施例仅为例示说明之用,而不应被解释为对本发明实施的限制。
实施例1载药纳米颗粒AMP-Cypate@GNP的制备
首先,使用MBHA树脂5倍当量的氨基酸,加入HBTU和HOBt并在DMF中激活偶联,每次持续45分钟。
其次,使用哌啶/DMF(20%,v/v)脱去氨基酸上的Fmoc保护基团,每次持续30分钟。重复上述步骤直至序列合成,再使用TFA/TIS/DCM(1:5:94)将序列N端的Fmoc基团切割掉,N端暴露的氨基与5倍过量的游离Cypate在DIPEA存在的情况下偶联12小时,形成序列AMP-Cypate。通过TFA、EDT、去离子水和TIS(94:2.5:2.5:1,v/v/v/v)的裂解混合物将肽链AMP-Cypate从树脂上切割下来,并通过高效液相进行制备纯化。AMP-Cypate的分子量通过LC-MS确认:m/z计算为[M+2H]2+1076.9,实测值1076.3。
最后,将5mL GNP(4mg/mL)、2mg EDC和2mg NHS在pH≈7下连续搅拌30分钟,以激活明胶纳米颗粒的羧基。将AMP-Cypate滴加到GNP溶液中。将pH值调至7后,将混合物超声处理30分钟。最后,将溶液离心除去未反应的AMP-Cypate,用PBS洗涤3次,冻干得到AMP-Cypate@GNP。
实施例2未载药的空白微针贴片制备
空白微针主要由物理惰性聚合物PVP K-30和重组人III型胶原蛋白(Col III)组成的聚合物基质组成,制备方法为:
首先,将PVP溶于超纯水中(1g PVP加1mL超纯水),加入Col III 0.20g混合,配置成混合溶液,即聚合物基质溶液;
其次,将1mL的聚合物基质溶液浇注到微针模具上,将模具以2200g离心15分钟;最后,在37℃的烘箱中干燥48小时后,小心地剥离微针贴片,将所得微针贴片储存在密封的孔板中以供进一步研究。
实施例3细菌响应性微针贴片制备
细菌响应性微针贴片由细菌响应型载药纳米颗粒和聚合物基质组成,可将载药纳米颗粒递送至慢性伤口感染的病灶部位,对糖尿病大鼠足部的慢性伤口愈合显示出出色的治疗效果。该微针贴片的制备方法具体为:
首先,将浓度为10μg/mL载药纳米颗粒(AMP-Cypate@GNP)的乙醇悬浮液(0.2mL)浇注到装载有微针贴片的模具上,将覆盖的模具以2000g离心并在空气流下干燥,该过程重复三遍;
其次,将1mL聚合物基质溶液浇注到微针模具上,将模具以2200g离心15分钟;最后,在37℃的烘箱中干燥48小时后,小心地剥离微针贴片,将所得微针贴片储存在密封的孔板中以供进一步研究。
实施例4载药纳米颗粒体外抗菌活性测定
将250μL AMP-Cypate@GNP与1mL金黄色葡萄球菌培养物(107CFU/mL)混合并孵育1小时。然后,将金黄色葡萄球菌和AMP-Cypate@GNP的混合物用NIR激光(808nm,1.5W/cm2)照射6分钟,完成后稀释涂板并放入生化培养箱培养后,对琼脂板上的菌落进行计数(n≥3)以评估AMP-Cypate@GNP的抗菌性能。
实施例5细菌Live/Dead测定
通过活/死细菌染色试验验证使用AMP-Cypate@GNP样品处理并照射前后细菌的活力。首先加入2mL LB液体培养基和50μL样品至NEST玻璃底培养皿中,然后加入100μL菌悬液培养24小时。PBS冲洗后用2.5%戊二醛固定1.5小时。所有实验组处理均在室温下与含有3μM SYTO 9和3μM碘化丙啶(PI)的染料溶液混合30分钟,最后通过共聚焦显微镜(LSM710,Carl Zeiss)成像。根据制造商的说明,活细菌细胞用SYTO 9染料(绿色)染色,而死细菌细胞因细胞壁和细胞膜受损而用碘化丙啶染料(红色)标记。
实施例6生物相容性测定
基于MTT法测定材料的生物相容性,用小鼠成纤维细胞(L929)和人脐静脉内皮细胞(HUVEC)评估了载药纳米颗粒的细胞毒性。首先,将L929细胞和HUVEC细胞接种在96孔微孔板(每孔104个细胞)上过夜,并用不同浓度(0、2、4、6、8和10μg/mL)的载药纳米颗粒处理,孵育24小时后,通过用酶标仪测量490nm处的吸光度来评估L929细胞和HUVEC细胞的活力,以评估载药纳米颗粒的细胞毒性。
实施例7创面修复实验
具体实验步骤为:
(1)糖尿病大鼠足部细菌感染创伤模型
糖尿病大鼠(GK,12周,~300g)购自常州凯文斯生物科技有限公司,并在实验室适应2周。动物保持禁食状态,并在Accu-Chek Active血糖仪的帮助下测量血糖水平。选择空腹血糖水平处于15-17mmol/L的那些动物进行研究。
为了构建感染的糖尿病大鼠伤口模型,首先使用一次性活检穿孔器在糖尿病大鼠的上背部创建一个贯穿肉膜的椭圆形全层伤口(8mm×6mm),然后接种。在伤口处接种细菌(107CFU/mL的S.aureus)并原位培养48小时形成生物膜。造模期间大鼠单笼饲养,放置玩具陪伴,自由饮水、进食。造模结束后,每个大鼠创口无明显区别,细菌感染部位发黄,外周发红,周围组织水肿明显。
(2)动物分组
将35个大鼠随机分为7组:
A组为对照组,给药剂量为200μL PBS/伤口,外敷;
B组为GNP,给药剂量为200μL GNP/伤口,外敷;
C组为AMP-Cypate@GNP,给药剂量为200μL/伤口,外敷;
D组为AMP-Cypate@GNP,给药剂量为200μL/伤口,外敷加光照;
E组为空白微针贴剂(MN),外敷;
F组为载药微针贴剂(MN/AMP-Cypate@GNP),外敷;
G组为载药微针贴剂(MN/AMP-Cypate@GNP),外敷加光照。
(3)在伤口造模后,分别将A组、B组、C组、D组、E组、F组、G组所用的敷料应用到大鼠足部的创口上,并于造模后第1、5、10、15、20日观察每组创面情况(见图9)。
经观察,给药治疗后随着修复时间的延长,各组均逐渐呈现伤口缩小的趋势。结果如附图所示,可以看出使用本发明载药微针贴剂糖尿病大鼠足感染伤口部位愈合速度明显大于其他对照组,光照处理后伤口愈合更加明显且瘢痕增生减少。
以上述依据本发明的理想实施例为启示,通过上述的说明内容,相关工作人员完全可以在不偏离本项发明技术思想的范围内,进行多样的变更及修改。本项发明的技术性范围并不局限于说明书上的内容,必须要根据权利要求范围来确定其技术范围。

Claims (8)

1.一种细菌响应性微针贴片,其特征在于,所述细菌响应性微针贴片由微针贴片、细菌响应性载药纳米颗粒AMP-Cypate@GNP和聚合物基质组成。
2.如权利要求1所述的细菌响应性微针贴片,其特征在于,所述细菌响应性载药纳米颗粒AMP-Cypate@GNP是由明胶纳米粒子(GNP)自组装并通过脱水缩合反应与抗菌肽(AMP-Cypate)耦合形成。
3.如权利要求2所述的细菌响应性微针贴片,其特征在于,所述抗菌肽AMP-Cypate的制备方法为:使用Fmoc固相合成法合成抗菌肽序列GKRWWKWWRR,再利用脱水缩合反应将荧光染料Cypate偶联至抗菌肽上合成最终序列GKRWWKWWRR-Cypate,简称AMP-Cypate。
4.如权利要求1所述的细菌响应性微针贴片,其特征在于,所述聚合物基质由物理惰性聚合物PVP K-30和重组人III型胶原蛋白Col III组成。
5.如权利要求1所述的细菌响应性微针贴片,其特征在于,所述聚合物基质的制备方法为:将PVP溶于超纯水中,加入Col III混合,配置成混合溶液,4℃保存备用。
6.如权利要求5所述的细菌响应性微针贴片,其特征在于,所述1g PVP加1mL超纯水;PVP与Col III的质量比为1:0.2。
7.一种如权利要求1所述的细菌响应性微针贴片的制备方法,其特征在于,所述微针贴片是通过溶剂浇铸方法制备的,制备方法步骤如下:
首先,将浓度为10μg/mL细菌响应性载药纳米颗粒的乙醇悬浮液浇注到装载有微针贴片的模具上,将覆盖的模具以2000g离心并在空气流下干燥,该过程重复三遍;
其次,将1mL聚合物基质溶液浇铸到沉积有细菌响应性载药纳米颗粒的微针模具上,将模具以2200g离心15分钟;
最后,在37℃的烘箱中干燥48小时后,小心地剥离微针贴片,并将所得微针贴片储存在密封的孔板中以供进一步研究。
8.一种如权利要求1所述的细菌响应性微针贴片的应用,其特征在于,所述微针贴片作为伤口敷料可用于治疗伤口和其他容易感染的部位。
CN202210098241.9A 2022-01-27 2022-01-27 一种细菌响应性微针贴片及其制备方法和应用 Active CN114432276B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210098241.9A CN114432276B (zh) 2022-01-27 2022-01-27 一种细菌响应性微针贴片及其制备方法和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210098241.9A CN114432276B (zh) 2022-01-27 2022-01-27 一种细菌响应性微针贴片及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN114432276A true CN114432276A (zh) 2022-05-06
CN114432276B CN114432276B (zh) 2024-01-23

Family

ID=81368866

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210098241.9A Active CN114432276B (zh) 2022-01-27 2022-01-27 一种细菌响应性微针贴片及其制备方法和应用

Country Status (1)

Country Link
CN (1) CN114432276B (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114948849A (zh) * 2022-05-13 2022-08-30 苏州大学附属第一医院 一种含trem1抑制剂的微针、微针系统及其制备方法
CN115025385A (zh) * 2022-06-02 2022-09-09 郑州大学 一种差速释药的微针贴片及其制备方法和应用
CN115998669A (zh) * 2023-01-10 2023-04-25 中国海洋大学 一种硫化铜纳米酶-抗菌肽-透明质酸复合微针及其制备方法和应用
RU2804809C1 (ru) * 2023-04-19 2023-10-06 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Способ изготовления биодеградируемого микроигольного накожного патча для отсроченной гемостимуляции онкологических больных

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190255349A1 (en) * 2013-05-23 2019-08-22 The United States of America Represented by the Secretary of Navy Method of treating multi-drug resistance biofilm using targeted laser and antibiotics
CN113713089A (zh) * 2021-09-18 2021-11-30 西北大学 可消除伤口处生物膜的可溶解微针贴片及制备方法和应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190255349A1 (en) * 2013-05-23 2019-08-22 The United States of America Represented by the Secretary of Navy Method of treating multi-drug resistance biofilm using targeted laser and antibiotics
CN113713089A (zh) * 2021-09-18 2021-11-30 西北大学 可消除伤口处生物膜的可溶解微针贴片及制备方法和应用

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114948849A (zh) * 2022-05-13 2022-08-30 苏州大学附属第一医院 一种含trem1抑制剂的微针、微针系统及其制备方法
CN115025385A (zh) * 2022-06-02 2022-09-09 郑州大学 一种差速释药的微针贴片及其制备方法和应用
CN115998669A (zh) * 2023-01-10 2023-04-25 中国海洋大学 一种硫化铜纳米酶-抗菌肽-透明质酸复合微针及其制备方法和应用
CN115998669B (zh) * 2023-01-10 2024-05-24 中国海洋大学 一种硫化铜纳米酶-抗菌肽-透明质酸复合微针及其制备方法和应用
RU2804809C1 (ru) * 2023-04-19 2023-10-06 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Способ изготовления биодеградируемого микроигольного накожного патча для отсроченной гемостимуляции онкологических больных

Also Published As

Publication number Publication date
CN114432276B (zh) 2024-01-23

Similar Documents

Publication Publication Date Title
CN114432276B (zh) 一种细菌响应性微针贴片及其制备方法和应用
Rajendran et al. A review on nanoparticle based treatment for wound healing
Priya et al. Bilayer cryogel wound dressing and skin regeneration grafts for the treatment of acute skin wounds
Lei et al. Degradable microneedle patches loaded with antibacterial gelatin nanoparticles to treat staphylococcal infection-induced chronic wounds
Sethuram et al. Therapeutic applications of electrospun nanofibers impregnated with various biological macromolecules for effective wound healing strategy–a review
Ye et al. Keratin-based wound dressings: From waste to wealth
CN109456389B (zh) 一种抗菌肽、抗菌肽水凝胶及其制备方法
Zhao et al. Glucose oxidase-loaded antimicrobial peptide hydrogels: Potential dressings for diabetic wound
US20190202998A1 (en) Visible light-curable water-soluble chitosan derivative, chitosan hydrogel, and preparation method therefor
Meng et al. Recent advances in bacterial cellulose-based antibacterial composites for infected wound therapy
Zhou et al. A carrier-free, dual-functional hydrogel constructed of antimicrobial peptide Jelleine-1 and 8Br-cAMP for MRSA infected diabetic wound healing
US10836872B2 (en) Visible light-curable water-soluble chitosan derivative, chitosan hydrogel, and preparation method therefor
CN113577012B (zh) 微针贴片及其在伤口愈合中的应用
Cao et al. Animal tissue-derived biomaterials for promoting wound healing
Zahoor et al. Diabetic wound healing potential of silk sericin protein based hydrogels enriched with plant extracts
Al Mamun et al. Oxygen releasing patches based on carbohydrate polymer and protein hydrogels for diabetic wound healing: A review
Liu et al. Biomembrane-based nanostructure-and microstructure-loaded hydrogels for promoting chronic wound healing
CN1197552C (zh) 应用抗炎剂的制剂
Rivero et al. Nanofibrous scaffolds for skin tissue engineering and wound healing applications
Mahmoud et al. Rapid release polymeric fibers for inhibition of Porphyromonas gingivalis adherence to Streptococcus gordonii
CN114699387B (zh) 一种核壳结构的载药纳米颗粒及其制备方法和应用
Guo et al. A novel bola-molecular self-assembling hydrogel for enhancing diabetic wound healing
Noh et al. Preparation of drug-immobilized anti-adhesion agent using visible light-curable alginate derivative containing furfuryl group
Tseomashko et al. New hybrid materials for wound cover dressings
Sharon Sofini et al. Nanostructure-assisted wound dressing materials: A literature review

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant